Regimen Reference Order

HEME – decitabine and cedazuridine (INQOVI®)

ARIA: HEME – [decitabine + cedazuridine]

Planned Course: **Until disease progression or unacceptable toxicity (1 cycle = 28 days)**
Indication for Use: **Myelodysplastic syndrome**

Proceed with treatment if:
ANC equal to or greater than 1 x 10^9/L AND Platelets equal to or greater than 50 x 10^9/L

- **Contact Hematologist if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – HEME – decitabine and cedazuridine (INQOVI®)

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 mg	Orally once daily 30 minutes pre-chemotherapy on **Days 1 to 5** **(Self-administered at home)**
decitabine and cedazuridine (combination tablet INQOVI®)	35 mg/100 mg (1 tablet)	Orally once daily on an empty stomach on **Days 1 to 5** Swallow whole **(Self-administered at home)**
decitabine and cedazuridine combination (INQOVI®) available dosage strength: 35 mg/100 mg tablet **Classification: Cytotoxic, Hazardous**		

REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, urea, liver enzymes, total bilirubin, albumin, electrolytes and glucose as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting (including Days 1 to 5)

INSTRUCTIONS FOR PATIENT

- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Not applicable